TL;DR: Semaglutide (Ozempic/Wegovy, the “skinny jab”) hits one incretin receptor — GLP-1. Retatrutide, nicknamed the “Triple G” (and “Godzilla” on the forums), hits three: GLP-1, GIP, and glucagon. That third receptor, glucagon, adds energy expenditure on top of appetite suppression, which is why retatrutide reached ~24% weight loss in its Phase 2 trial versus semaglutide’s ~15%. The catch: retatrutide is still investigational, while semaglutide is long-established.
Retatrutide and semaglutide sit at opposite ends of the incretin evolution: semaglutide is the proven single-receptor drug that started the wave, and retatrutide is the newest triple-receptor agonist chasing the biggest weight-loss numbers yet. This guide compares them on mechanism, data, and status.
One Receptor vs Three
- Semaglutide is a single GLP-1 receptor agonist — appetite suppression, slowed gastric emptying, glucose-dependent insulin release.
- Retatrutide is a triple agonist — GLP-1 and GIP (like tirzepatide) plus the glucagon receptor, which increases energy expenditure and hepatic fat handling.
- 1
GLP-1 (both)
Appetite suppression and glucose control — semaglutide stops here.
- 2
GIP (retatrutide)
Amplifies the metabolic and weight effect.
- 3
Glucagon (retatrutide)
Adds energy expenditure — the third lever semaglutide does not pull.
Head-to-Head Comparison
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Class | GLP-1/GIP/glucagon triple agonist | GLP-1 agonist |
| Nicknames | ”Triple G”, “Godzilla" | "skinny jab”, Ozempic |
| Status | Investigational (Phase 3) | Approved, long track record |
| Top weight loss* | ~24% | ~15% |
| Dosing | weekly, titrated 1→12mg | weekly, 0.25→2.4mg |
*Based on trial data at maximum studied doses.
Approximate figures from the trial programs; retatrutide is Phase 2/3, semaglutide is fully approved. Individual response varies widely.
Retatrutide’s larger figure comes with an important caveat: it is still investigational, so its long-term safety record is far shorter than semaglutide’s. For where the dual agonist tirzepatide sits between them, see retatrutide vs tirzepatide and the full three-way GLP-1 comparison.
Status: Proven vs Promising
This is the real dividing line, more than the mechanism:
- Semaglutide has years of real-world use, an oral form (Rybelsus), and an established safety profile. See what is semaglutide.
- Retatrutide is in late-stage trials with the strongest weight-loss data reported so far, but not the long tail of safety data. See what is retatrutide and retatrutide dosing and titration.
Research vials are available for semaglutide and retatrutide; model any vial and dose in the reconstitution calculator.
Side Effects
Both carry the GLP-1 gastrointestinal profile; retatrutide’s glucagon activity adds its own considerations:
- Both: nausea, reduced appetite, GI effects — dose-dependent, managed by slow titration. See GLP-1 side-effects management.
- Retatrutide specifically: the glucagon component means glucose and heart-rate parameters are watched closely in trials; a transient dysesthesia (tingling) has also been reported at high doses — see retatrutide dysesthesia.
Safety, Legality & Research Disclaimers
Semaglutide is an approved medicine; retatrutide is investigational. Both are handled here as research peptides, not for self-administration outside appropriate oversight. They are laboratory research chemicals for qualified individuals and legitimate research purposes only. Regulatory status varies by jurisdiction; researchers are responsible for compliance with applicable local laws and institutional requirements. Nothing here is medical advice.
FAQ
Is retatrutide more effective than semaglutide for weight loss?
In the trial data, yes — retatrutide reached ~24% weight loss at top dose versus semaglutide’s ~15%. The difference is mechanistic: retatrutide is a triple agonist (GLP-1, GIP, glucagon) while semaglutide activates GLP-1 alone. The important caveat is that retatrutide is still investigational, whereas semaglutide is fully approved with a long safety record.
What does “Triple G” mean for retatrutide?
“Triple G” is the common nickname for retatrutide, referring to its three receptor targets: GLP-1, GIP, and glucagon. Semaglutide, by contrast, is a single-G drug — GLP-1 only. Retatrutide is also called “Godzilla” on some forums for its large weight-loss numbers.
Can I buy retatrutide like semaglutide?
Retatrutide is investigational and not an approved medicine, so it does not have the pharmacy availability semaglutide does. It is handled strictly as a research compound. Semaglutide is approved in many jurisdictions but is treated here as a research peptide too.
What does the glucagon receptor add?
Glucagon-receptor activity increases energy expenditure and affects hepatic fat handling — a third mechanism on top of the appetite suppression (GLP-1) and metabolic amplification (GIP) that retatrutide shares with tirzepatide. Semaglutide does not activate the glucagon receptor at all.
References
- Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023.
- Research literature on semaglutide (GLP-1 agonist) weight-loss trials (STEP program).
Last updated: July 15, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption. See the retatrutide and semaglutide research pages for reconstitution detail.